Radio 223 Injection (Xofigo)

Approximately 240,000 men in the United States are expected to be diagnosed with prostate cancer in 2016. Although most are diagnosed at an early localized stage, up to 30% of cases will be repeated after surgical therapy or curative radiotherapy. Androgen deprivation therapy, either with surgical or gonadotropin releasing castration analogous to the hormone, is normally initiated to control the disease in people who have developed metastases. Unfortunately, almost all these cases will continue progressing. When patients turn to androgen deprivation therapy in the adjustment of "castration" levels of testosterone, patients receive the name of "castration-resistant". <a id="